Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)

NCT05462106 is registered in ClinicalTrials.gov with AC Immune SA as lead sponsor.

NCT NCT05462106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05462106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)
Lead sponsor
AC Immune SA
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 21, 2022
Completion date
April 30, 2029
Enrollment
304 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, amyloid plaque, beta-amyloid, dsad, prodromal alzheimer's disease